MeOPN Synthetic Antigen Constructs for Campylobacter Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Campylobacter jejuni (C. jejuni) are not commercially available, and existing immunogenic compositions are inadequate for effectively preventing or ameliorating diseases associated with C. jejuni infection, which causes significant morbidity and mortality, especially in developing countries.
Innovation Solution
Development of immunogenic synthetic constructs comprising methyl phosphoramidate (MeOPN) moieties, specifically MeOPN-2-Gal, MeOPN-4-Gal, and MeOPN-6-Gal monosaccharides, which are conjugated to carrier proteins like CRM197, and administered with adjuvants to induce an immune response, potentially offering broader serotype coverage and improved immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccine production methods are used, then commercial vaccine availability is limited, but development cost and time are excessive
Solution Approach 1:
The patent uses synthetic polysaccharide copies of the C. jejuni capsule structures (specifically MeOPN-containing polysaccharides) instead of requiring live bacteria or complex purification processes. This synthetic approach replicates the key immunogenic elements without the complications of traditional vaccine production, enabling more reliable and scalable manufacturing while maintaining immunogenicity.
Solution Approach 2:
The invention modifies the chemical structure parameters of the polysaccharide antigens by incorporating specific MeOPN (methyl phosphoramidate) groups at defined positions (O-2, O-4, or O-6 of galactose). This structural parameter change enhances immunogenicity and enables synthetic production, resolving the contradiction between vaccine reliability and manufacturing ease.
2Reliability
If synthetic constructs with MeOPN moieties are used, then immunogenicity is improved, but manufacturing complexity increases
Solution Approach 1:
The synthetic construct is divided into discrete, well-defined segments: specific monosaccharide units (galactose with MeOPN at O-2, O-4, or O-6), repeating trisaccharide or tetrasaccharide blocks, and defined polymer lengths. This segmentation simplifies the manufacturing process by allowing modular synthesis of standardized immunogenic units that can be assembled reproducibly, reducing overall complexity while maintaining high immunogenicity.
Data Source
AI summary
The invention relates to immunogenic synthetic constructs capable of inducing an immune response against Campylobacter jejuni (C. jejuni) in a subject comprising one or more monosaccharides comprising one or more MeOPN moieties. Specifically, the invention relates to immunogenic synthetic constructs capable of inducing an immune response against C. jejuni in a subject comprising one or more MeOPN-6-Gal monosaccharides, one or more MeOPN-4-Gal monosaccharides, and/or one or more MeOPN-2-Gal monosaccharides. The invention also relates to compositions comprising the immunogenic synthetic constructs, and methods of inducing an immune response against C. jejuni in a subject comprising administering the immunogenic synthetic constructs, and/or compositions comprising the immunogenic synthetic constructs, to the subject. Methods of treating, preventing, or ameliorating a C. jejuni bacterial infection in a subject comprising administering to the subject one or more doses of immunoglobulins directed to one or more of the MeOPN moieties are also contemplated.